NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights

-- Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the primary endpoint with 63.4% median reduction in LDL-C -- -- Announced...

Related Keywords

Brooklyn ,Florida ,United States ,Netherlands ,Russia ,Japan ,Ukraine ,Naarden ,Noord Holland ,Miami ,Japanese ,Michael Davidson ,Matthew Philippe ,Hannah Deresiewicz ,Company Phase ,Neither The Company ,Newamsterdam Pharma Company ,Exchange Commission ,Development Rd Expenses ,National Lipid Association ,Company Contact ,Company Options ,Clinical Development Updates ,Newamsterdam Pharma Companynv Nasdaq ,Chief Executive Officer ,Development Updates ,Scientific Sessions ,Corporate Updates ,Potential Milestones ,Investor Relations ,Consolidated Statements Of Profit Or Loss ,Consolidated Statements Of Financial Position ,Consolidated Statements Of Cash Flows ,Markets ,